Compare YOUL & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YOUL | ATNM |
|---|---|---|
| Founded | 2020 | 2000 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.1M | 31.4M |
| IPO Year | 2024 | 2013 |
| Metric | YOUL | ATNM |
|---|---|---|
| Price | $0.25 | $1.47 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 184.0K | ★ 233.4K |
| Earning Date | 10-15-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 14.17 |
| EPS | N/A | ★ 0.71 |
| Revenue | N/A | ★ $90,000.00 |
| Revenue This Year | $12.08 | $38,788.89 |
| Revenue Next Year | $10.04 | N/A |
| P/E Ratio | ★ N/A | $2.14 |
| Revenue Growth | N/A | ★ 11.11 |
| 52 Week Low | $0.21 | $0.74 |
| 52 Week High | $2.13 | $1.72 |
| Indicator | YOUL | ATNM |
|---|---|---|
| Relative Strength Index (RSI) | 36.44 | 61.79 |
| Support Level | $0.21 | $0.91 |
| Resistance Level | $0.56 | $1.66 |
| Average True Range (ATR) | 0.06 | 0.14 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 36.55 | 74.65 |
Youlife Group Inc is a blue-collar lifetime service platform in China, dedicated to serving the needs throughout the entire life cycle of the blue-collar talent. It provides blue-collar lifetime services to students, blue-collar talent, and corporate customers. Its segments are the vocational education segment, which engages in the provision of vocational education entrusted management services, self-operated vocational school services, and Others; the HR recruitment segment engages in the provision of HR recruitment services regarding blue-collar talent to customers; the employee management segment engages in the provision of labor outsourcing services, labor dispatch services and others; and the market service segment engages in the provision of value-added services.
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of targeted radiotherapies using its Antibody Radiation Conjugates (ARCs) platform, which combines monoclonal antibodies with radioisotopes to selectively target and destroy cancer cells. The company's product candidates include Iomab-B, an iodine-131 based radiotherapy for conditioning prior to hematopoietic stem cell transplantation, and Actimab-A, an actinium-225 based radiotherapy in clinical development for acute myeloid leukemia. The company is also advancing additional programs, including Iomab-ACT for cell and gene therapy conditioning and other preclinical candidates targeting solid tumors.